Skip to content
Medical Health Aged Care

Monash Expert: Understanding Australia’s COVID-19 epidemics

Monash University < 1 mins read

As the world deals with a new Covid-19 variant, XEC, new Monash University-led research has shown how important short-lived immunity and immune-escape of new variants have been to driving waves of transmission in Australia.

Available to comment:

Associate Professor James Trauer, Head of the Epidemiological Modelling Unit for the School of Public Health and Preventive Medicine
Contact: +613 9903 4840, or [email protected]  
Read more of Associate Professor Trauer’s commentary in Monash Lens.

  • The status of COVID-19 in Australia now
  • The likely impact of COVID-19 moving forward
  • The need for continued vaccination

The following can be attributed to Associate Professor Trauer:

“Our research showed that Australia's major Omicron waves in 2022 were driven by substantial immune-escape of new variants combined with immunity that protected against infection only lasting around three to four months.

“The ‘shadow lockdown’ in summer 2021-2022, when Australians reduced their social interaction in the absence of a government mandate, likely protected us from a considerably larger first epidemic wave. Only around 20 to 40 per cent per cent of all COVID-19 episodes were notified through our surveillance systems, even with our highest levels of testing.

“I think ATAGI’s current guidelines strike the right balance and that people should get vaccinated if they are at-risk and eligible. As the virus continues to evolve, the more recent vaccines are more protective against the current variants - so it's more important if you haven't been vaccinated since the start of last year.” 

For more Monash media stories visit our news & events site: monash.edu/news
For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or [email protected]

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 17/12/2025
  • 06:00
Leukaemia Foundation

Leukaemia Foundation welcomes South Australian Government commitment to establish dedicated CAR T therapy service

The Leukaemia Foundation has welcomed the announcement by theMalinauskas Labor Government that South Australia is establishing a dedicated CAR T-cell therapy service as a line of treatment for people living with blood cancer – marking a major advancement in cancer care in the State. The new service, expected to commence by mid-2026, will significantly improve access to this highly specialised, life-saving treatment and reduce the need for South Australians to travel interstate for care. Leukaemia Foundation Chief Executive Officer Chris Tanti said the announcement represented a huge win for blood cancer patients and their families. “This is a landmark step…

  • Medical Health Aged Care
  • 17/12/2025
  • 01:10
WW International Inc.

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that lastNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated experience bringing together comprehensive support for members on GLP-1 medications, personalised nutrition, behavioural support, coaching, and community within a redesigned app and digital platform. Built for a new era of weight management and long-term health, the new integrated offering delivers coordinated, evidence-based…

  • Medical Health Aged Care
  • 16/12/2025
  • 12:11
Esco Aster Pte. Ltd.

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE–BUSINESS WIRE– Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.